How Pharma Can Transition to Non-animal Studies for Investigational Drugs
Pharma companies can ease the transition to non-animal studies for investigational drugs by leveraging NAMs…
CertaraJuly 25, 2025
End of Animal Testing? Advancing Drug Development Alternatives
The FDA has stated that the pharma industry must transition to using in vitro assays,…
CertaraJuly 21, 2025
How is the pharmaceutical industry addressing global health inequities?
Explore Karen Rowland Yeo's insights on using Model-Informed Drug Development to address global health equities…
CertaraJune 17, 2025
Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance
With the release of the draft ICH M15 guidance, MIDD is no longer optional -…
CertaraJune 11, 2025
Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance
SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…
CertaraMay 23, 2025
Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?
Part 3 in November: Understanding the Supersaturated Dissolution in the Digestive Tract with Modeling &…
CertaraMay 12, 2025
Essentials of Model-informed Drug Development in Oncology
Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs.…
CertaraMay 2, 2025
